# Efficacy of Dapagliflozin on Recurrence After Catheter Ablation for Atrial Fibrillation

> **NCT06433479** · NA · COMPLETED · sponsor: **Beijing Anzhen Hospital** · enrollment: 200 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** Dapagliflozin 10 mg per day for 3 months after initial catheter ablation

## Key facts

- **NCT ID:** NCT06433479
- **Lead sponsor:** Beijing Anzhen Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-07-15
- **Primary completion:** 2025-07-01
- **Final completion:** 2025-07-01
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2025-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06433479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06433479, "Efficacy of Dapagliflozin on Recurrence After Catheter Ablation for Atrial Fibrillation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06433479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*